News

Optimal use of off-patent medicines: the offer you cannot (afford to) refuse

Medaxes is pleased to announce that the Board of Directors has appointed Jasmien Coenen as the new Managing Director. She takes over the helm from Joris Van Assche who, to our great sadness, unexpectedly passed away on 8 August.

It is with great sadness that we inform you of the sudden decease of Joris Van Assche.

As Medaxes community, our thoughts are with his wife and children, his family and friends. We sincerely offer them our deepest sympathy.

There are no words for our disbelief and grief. Joris leaves a huge professional and personal void for us all. Not only was he our highly driven and unequalled Director, he was a warm-hearted man with the right values, a mediator and confidant for Medaxes and the whole community.

Thank you for everything, Joris. We will never forget you.

Cheap medicines in particular are at risk of falling victim to this.

Off patent medicines account for 70% of those dispensed in Europe for the most prominent diseases such as cancer, diabetes, cardiovascular care, infectious diseases, and others. Between 70-90% of Intensive Care Unit (ICU), and emergency medicines are off patent. Our sector currently has over 400 manufacturing sites in Europe. Therefore, the off patent medicines industry sector must be included in the 'Important Project of Common European Interest' (IPCEI) on Health.

Please find here the press release of our European association, Medicines for Europe.

Dutch: Edito 'Business as usual?', Europese off-patent sector zeer bezorgd over negatieve impact van torenhoge inflatie op beschikbaarheid van geneesmiddelen, Biosimilars in het medicomut-akkoord, #NoFilter Interview K. Straetmans (APB) & J. Van Assche (Medaxes) - Deel 2

French: Edito 'Business as usual?', Le secteur européen des médicaments hors brevet très préoccupé par l'impact négatif de l'inflation galopante sur la disponibilité des médicaments, Médicaments biosimilaires dans l'accord médicomut, #NoFilter: interview du pharmacien Koen Straetmans (APB) et de Joris Van Assche (Medaxes) -

Dutch: Edito, #NoFilter Interview K. Straetmans (APB) & J. Van Assche (Medaxes), Stakeholders aan het woord Generic medicines day

French: Edito, #NoFilter Interview K. Straetmans (APB) & J. Van Assche (Medaxes), Parole à nos stakeholders Generic medicines day

Scroll down or discover here the updated (October 2021) Facts & Figures Generic medicines in Belgium brochure.

Missed out on the Generic medicines day webinar of 28 October 2021?

Scroll down the homepage of our website to replay.

Participate to the Generic medicines day webinar! Register now!

Scroll down or discover here: Facts & Figures generic medicines in Belgium - Facts & figures biosimilar medicines in Belgium

With the support of the Belgian and Luxembourg Competent Authorities, in 2018 the pharmaceutical industry launched the 'e-PIL' pilot project in Belgian and Luxembourg hospitals. The project is the result of a derogation obtained from the European Commission. 

Replay of the Generic Medicines Day webinar (in Dutch and French)

With the support of the Belgian and Luxembourg Competent Authorities, in 2018 the pharmaceutical industry launched the 'e-PIL' pilot project in Belgian and Luxembourg hospitals. The project is the result of a derogation obtained from the European Commission. In this pilot project, a selection of medicines on the Belgian and Luxembourg market are not accompanied by their patient paper inserted leaflet (PIL). 

For the treatment of the Corona virus, Medaxes refers to the scientific guidelines issued by the scientific institutions of our country.

These informations are regularly updated, taking into account the latest scientific findings. For more information, please click on Sciensano Epidemio